# Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

> **NCT05983094** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 181 (estimated)

## Conditions studied

- Breast Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Utidelone
- **DRUG:** Carboplatin
- **DRUG:** Epirubicin
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT05983094
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 181 (ESTIMATED)
- **Last updated:** 2023-08-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983094, "Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05983094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*